Histotripsy (NCT07766187)

Name: Histotripsy trial for Intrahepatic Cholangiocarcinoma (NCT07766187)
Uploaded: 2026-10-31T22:20:21.888Z
Duration: 1 min 12 s
Description: Histotripsy trial for Intrahepatic Cholangiocarcinoma (NCT07766187). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07766187.

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma: a one-minute explainerNCT077661871 min

Histotripsy trial for Intrahepatic Cholangiocarcinoma (NCT07766187). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with intrahepatic cholangiocarcinoma that is unresectable, or who cannot undergo surgery. Disease must remain controlled after eighteen weeks of first-line chemotherapy and durvalumab.

The idea: histotripsy uses focused ultrasound to destroy tumor tissue without heat. Durvalumab blocks PD-L1 immune suppression. Patients continue monthly durvalumab and receive histotripsy under general anesthesia. Biopsies before and after treatment sample a separate tumor or an untreated region. Researchers assess immune changes and side effects.

This phase 2 study plans 12 patients. John Swietlik leads at the University of Wisconsin’s recruiting Madison site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.